Immune genes are associated with human glioblastoma pathology and patient survival

BMC Medical Genomics

Volumn 5, Issue , 2012, Pages

  Vauléon, Elodie ^a,b   Tony, Avril ^a,b   Hamlat, Abderrahmane ^c   Etcheverry, Amandine ^b,c   Chiforeanu, Dan Cristian ^c   Menei, Philippe ^d   Mosser, Jean ^b,c   Quillien, Véronique ^a,b   Aubry, Marc ^b  

^a Eugène Marquis Hospital   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Glioblastoma; Immune system; Survival

Indexed keywords

CYTOKINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ADULT; ARTICLE; BONE MARROW CELL; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; GLIOBLASTOMA; HUMAN; IMMUNE SYSTEM; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GLIOBLASTOMA; HUMANS; IMMUNITY; MALE; MIDDLE AGED; MOLECULAR SEQUENCE ANNOTATION; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROMOTER REGIONS, GENETIC; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870292778     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-5-41     Document Type: Article

References (56)

1. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. N Engl J Med 2005 352 987 996 10.1056/NEJMoa043330 15758009
2. A 4-gene signature associated with clinical outcome in high-grade gliomas. De Tayrac M, Aubry M, Saikali S, Etcheverry A, Surbled C, Guenot F, Galibert MD, Hamlat A, Lesimple T, Quillien V, et al. Clin Cancer Res 2011 17 317 327 10.1158/1078-0432.CCR-10-1126 21224364
3. Gene expression profiling of gliomas strongly predicts survival. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF, Cancer Res 2004 64 6503 6510 10.1158/0008-5472.CAN-04-0452 15374961
4. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Li A, Walling J, Ahn S, Kotliarov Y, Su Q, Quezado M, Oberholtzer JC, Park J, Zenklusen JC, Fine HA, Cancer Res 2009 69 2091 2099 19244127
5. Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data. Petalidis LP, Oulas A, Backlund M, Wayland MT, Liu L, Plant K, Happerfield L, Freeman TC, Poirazi P, Collins VP, Mol Cancer Ther 2008 7 1013 1024 10.1158/1535-7163.MCT-07-0177 18445660
6. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al. Cancer Cell 2006 9 157 173 10.1016/j.ccr.2006.02. 019 16530701
7. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. Cancer Cell 2010 17 98 110 10.1016/j.ccr.2009.12. 020 20129251
8. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, et al. Cancer Res 2009 69 9065 9072 10.1158/0008-5472.CAN-09-2307 19920198
9. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, et al. Cancer Res 2003 63 1602 1607 12670911
10. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I, Nozaki M, Diserens AC, Hamou MF, Dietrich PY, et al. Cancer Res 2003 63 6613 6625 14583454
11. Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking. Lachance DH, Yang P, Johnson DR, Decker PA, Kollmeyer TM, McCoy LS, Rice T, Xiao Y, li-Osman F, Wang F, et al. Am J Epidemiol 2011 174 574 581 10.1093/aje/kwr124 21742680
12. Role of medical history in brain tumour development. Results from the international adult brain tumour study. Schlehofer B, Blettner M, Preston-Martin S, Niehoff D, Wahrendorf J, Arslan A, Ahlbom A, Choi WN, Giles GG, Howe GR, et al. Int J Cancer 1999 82 155 160 10.1002/(SICI)1097-0215(19990719)82:2<155:: AID-IJC1>3.0.CO;2-P 10389745
13. Circulating levels of the innate and humoral immune regulators CD14 and CD23 are associated with adult glioma. Zhou M, Wiemels JL, Bracci PM, Wrensch MR, McCoy LS, Rice T, Sison JD, Patoka JS, Wiencke JK, Cancer Res 2010 70 7534 7542 10.1158/0008-5472.CAN-10-0815 20719886
14. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R, Grau S, Hiraoka N, Eckstein V, Ecker RC, et al. Clin Cancer Res 2011 17 4296 4308 10.1158/1078-0432.CCR-10-2557 21478334
15. Coexpression network analysis identifies transcriptional modules related to proastrocytic differentiation and sprouty signaling in glioma. Ivliev AE, t Hoen PA, Sergeeva MG, Cancer Res 2010 70 10060 10070 10.1158/0008-5472.CAN-10- 2465 21159630
16. Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Shirahata M, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N, Takahashi JA, Kato K, Clin Cancer Res 2007 13 7341 7356 10.1158/1078-0432.CCR-06-2789 18094416
17. An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Ducray F, De RA, Chinot O, Idbaih A, Figarella-Branger D, Colin C, Karayan-Tapon L, Chneiweiss H, Wager M, Vallette F, et al. Mol Cancer 2010 9 234 10.1186/1476-4598-9-234 20822523
18. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO, et al. Proc Natl Acad Sci USA 2005 102 5814 5819 10.1073/pnas.0402870102 15827123
19. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, De TN, Regli L, Wick W, Kouwenhoven MC, et al. J Clin Onco 2008 26 3015 3024 10.1200/JCO.2007.15.7164
20. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel PS, et al. Cancer Res 2006 66 159 167 10.1158/0008-5472.CAN-05-0077 16397228
21. Mechanisms of immunomodulation in human glioblastoma. Avril T, Vauleon E, Tanguy-Royer S, Mosser J, Quillien V, Immunotherapy 2011 3 42 44 10.2217/imt.11.39 21524170
22. Microglia in brain tumors. Graeber MB, Scheithauer BW, Kreutzberg GW, Glia 2002 40 252 259 10.1002/glia.10147 12379912
23. Distribution and characterization of microglia/macrophages in human brain tumors. Roggendorf W, Strupp S, Paulus W, Acta Neuropathol 1996 92 288 293 10.1007/s004010050520 8870831
24. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK, Liau LM, Horvath S, Mischel PS, Nelson SF, BMC Med Genomics 2008 1 52 10.1186/1755-8794-1-52 18940004
25. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, et al. Br J Cancer 2009 101 124 131 10.1038/sj.bjc.6605127 19536096
26. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, Etcheverry A, Hamlat A, Loussouarn D, Campion L, et al. J Neurooncol 2010 97 311 322 10.1007/s11060-009-0031-1 19841865
27. Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R. Langfelder P, Zhang B, Horvath S, Bioinformatics 2008 24 719 720 10.1093/bioinformatics/btm563 18024473
28. Geometric interpretation of gene coexpression network analysis. Horvath S, Dong J, PLoS Comput Biol 2008 4 1000117 doi:10.1371/journal.pcbi.1000117 18704157
29. Regression models and life-tables. Cox DR, Journal of the Royal Statistical Society Series B (Methodological) 1972 34 187 220
30. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, et al. Clin Cancer Res 2005 11 5515 5525 10.1158/1078-0432.CCR-05-0464 16061868
31. Presence and significance of NK cells in glioblastomas. Vaquero J, Coca S, Oya S, Martinez R, Ramiro J, Salazar FG, J Neurosurg 1989 70 728 731 10.3171/jns.1989.70.5.0728 2540292
32. Isolation and in vitro growth of glioma-infiltrating lymphocytes, and an analysis of their surface phenotypes. Sawamura Y, Abe H, Aida T, Hosokawa M, Kobayashi H, J Neurosurg 1988 69 745 750 10.3171/jns.1988.69.5.0745 3054014
33. Vaccination with MCP-1 cDNA transfectant on human malignant glioma in nude mice induces migration of monocytes and NK cells to the tumor. Nagai M, Masuzawa T, Int Immunopharmacol 2001 1 657 664 10.1016/S1567-5769(00)00050-3 11357878
34. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Alizadeh D, Zhang L, Brown CE, Farrukh O, Jensen MC, Badie B, Clin Cancer Res 2010 16 3399 3408 10.1158/1078-0432.CCR-09- 3087 20570924
35. Antitumor treatment using interleukin- 12-secreting marrow stromal cells in an invasive glioma model. Hong X, Miller C, Savant-Bhonsale S, Kalkanis SN, Neurosurgery 2009 64 1139 1146 10.1227/01.NEU.0000345646.85472.EA 19487894
36. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL, Black KL, Yu JS, Cancer Res 2006 66 8887 8896 10.1158/0008-5472.CAN-05-3448 16951206
37. Overview of cellular immunotherapy for patients with glioblastoma. Vauleon E, Avril T, Collet B, Mosser J, Quillien V, Clin Dev Immunol 2010 2010 1 18 article ID 689171
38. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. Komohara Y, Ohnishi K, Kuratsu J, Takeya M, J Pathol 2008 216 15 24 10.1002/path.2370 18553315
39. Activins and activin receptors in cell growth. Ying SY, Zhang Z, Furst B, Batres Y, Huang G, Li G, Proc Soc Exp Biol Med 1997 214 114 122 9034128
40. Activin receptor signaling regulates prostatic epithelial cell adhesion and viability. Simon DP, Vadakkadath MS, Wilson AC, Gallego MJ, Weinecke SL, Bruce E, Lyons PF, Haasl RJ, Bowen RL, Atwood CS, Neoplasia 2009 11 365 376 19308291
41. Activin signaling in microsatellite stable colon cancers is disrupted by a combination of genetic and epigenetic mechanisms. Jung B, Gomez J, Chau E, Cabral J, Lee JK, Anselm A, Slowik P, Ream-Robinson D, Messer K, Sporn J, et al. PLoS One 2009 4 8308 10.1371/journal.pone.0008308 20011542
42. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Tougeron D, Fauquembergue E, Rouquette A, Le PF, Sesboue R, Laurent M, Berthet P, Mauillon J, Di FF, Sabourin JC, et al. Mod Pathol 2009 22 1186 1195 10.1038/modpathol.2009.80 19503063
43. Recent advances in arginine metabolism: roles and regulation of the arginases. Morris SM Jr, Br J Pharmacol 2009 157 922 930 10.1111/j.1476-5381. 2009.00278.x 19508396
44. Human embryonic stem cells suppress T cell responses via arginase I-dependent mechanism. Yachimovich-Cohen N, Even-Ram S, Shufaro Y, Rachmilewitz J, Reubinoff B, J Immunol 2010 184 1300 1308 10.4049/jimmunol.0804261 20032293
45. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Tedder TF, Tuscano J, Sato S, Kehrl JH, Annu Rev Immunol 1997 15 481 504 10.1146/annurev.immunol.15.1.481 9143697
46. cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions. Wilson GL, Fox CH, Fauci AS, Kehrl JH, J Exp Med 1991 173 137 146 10.1084/jem.173.1.137 1985119
47. Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production. Mott RT, It-Ghezala G, Town T, Mori T, Vendrame M, Zeng J, Ehrhart J, Mullan M, Tan J, Glia 2004 46 369 379 10.1002/glia.20009 15095367
48. Glioblastoma cell growth is suppressed by disruption of Fibroblast Growth Factor pathway signaling. Loilome W, Joshi AD, Ap Rhys CM, Piccirillo S, Vescovi AL, Gallia GL, Riggins GJ, J Neurooncol 2009 94 359 366 10.1007/s11060-009-9885-5 19340397
49. Overexpression of high molecular weight FGF-2 forms inhibits glioma growth by acting on cell-cycle progression and protein translation. Lemiere S, Azar R, Belloc F, Gursel D, Pyronnet S, Bikfalvi A, Auguste P, Exp Cell Res 2008 314 3701 3711 10.1016/j.yexcr.2008.09.022 18930044
50. Radioresistance induced by the high molecular forms of the basic fibroblast growth factor is associated with an increased G2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells. Cohen-Jonathan E, Toulas C, Monteil S, Couderc B, Maret A, Bard JJ, Prats H, Ly-Schveitzer N, Favre G, Cancer Res 1997 57 1364 1370 9102225
51. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, Broggi G, Boiardi A, J Neurooncol 2003 62 297 303 10.1023/A:1023367223575 12777082
52. A gene for autosomal dominant sacral agenesis maps to the holoprosencephaly region at 7q36. Lynch SA, Bond PM, Copp AJ, Kirwan WO, Nour S, Balling R, Mariman E, Burn J, Strachan T, Nature Genet 1995 11 93 95 10.1038/ng0995-93 7550324
53. A novel human homeobox gene distantly related to proboscipedia is expressed in lymphoid and pancreatic tissues. Harrison KA, Druey KM, Deguchi Y, Tuscano JM, Kehrl JH, J Biol Chem 1994 269 19968 19975 7914194
54. The dual role of HLXB9 in leukemia. Ferguson S, Gautrey HE, Strathdee G, Pediatr Blood Cancer 2011 56 349 352 10.1002/pbc.22679 21069786
55. Ribosomal protein S19 interacts with macrophage migration inhibitory factor and attenuates its pro-inflammatory function. Filip AM, Klug J, Cayli S, Frohlich S, Henke T, Lacher P, Eickhoff R, Bulau P, Linder M, Carlsson-Skwirut C, et al. J Biol Chem 2009 284 7977 7985 10.1074/jbc.M808620200 19155217
56. Fibroblast growth factor-2 interacts with free ribosomal protein S19. Soulet F, Al ST, Roga S, Amalric F, Bouche G, Biochem Biophys Res Commun 2001 289 591 596 10.1006/bbrc.2001.5960 11716516